Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(33%)
Terminated
1(11%)

Phase Distribution

Ph phase_3
3
33%
Ph phase_2
2
22%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Terminated(1)
Other(2)

Detailed Status

Not yet recruiting3
Recruiting3
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (44.4%)
Phase 22 (22.2%)
Phase 33 (33.3%)

Trials by Status

not_yet_recruiting333%
terminated111%
unknown222%
recruiting333%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9